An improved method for experimental modeling of premature ovarian insufficiency in Wistar rats

Abstract

BACKGROUND: Despite an enormous progress in the field of reproductive endocrinology, the mechanisms of premature ovarian insufficiency have not been fully understood so far. Knowledge of the supposed causes and mechanisms underlying the development of premature ovarian insufficiency has expanded significantly in recent years, mainly due to advances in genetics and the creation of models for experimental research. The experimental modeling of premature ovarian insufficiency, which is as close as possible to the origin and development of the corresponding disease in humans, is effectively used to elaborate promising therapeutic approaches, in particular, to test new drugs or biologically active agents in order to study their preventive or curative effects. This article discusses the main methods of the experimental modeling of POI in laboratory animals. We have herein summarized the literature data related to the development of the clinical and morphological picture of the disease, with the advantages and disadvantages of each of the models analyzed.

AIM: The aim of this study was to modify the premature ovarian insufficiency modeling methodology to substantiate the effectiveness and to test new directions in drug therapy with subsequent implementation in clinical practice.

MATERIALS AND METHODS: The new method is based on the creation of an experimental premature ovarian insufficiency model in female Wistar rats. To obtain this model, experimental rats were randomized into two groups: 1) animals receiving cyclophosphamide at a dose of 150 mg/kg b.w. subcutaneously once (n = 10); 2) animals receiving 2 ml of saline intraperitoneally once (n = 9). On day10, the animals were removed from the experiment. After autopsy, a visual assessment of morphological changes in the ovaries was carried out, and a right-sided ovariectomy was performed.

RESULTS: When using the proposed model, the reproducibility rate of POI has reached 100%.

CONCLUSIONS: Our modification of the method ensures the creation of a highly reproducible premature ovarian insufficiency model in Wistar rats. Another significant advantage of this modeling method is its ease of implementation and economic efficiency.

Keywords

premature ovarian insufficiency / experimental model / Wistar rats / cyclophosphamide

References

[1] Kapoor E. Premature ovarian insufficiency. Curr Opin Endocr Metab Res. 2023;28. DOI: 10.1016/j.coemr.2023.100435

[2] Kapoor E. Premature ovarian insufficiency // Curr. Opin. Endocr. Metab. Res. 2023. Vol. 28. DOI: 10.1016/j.coemr.2023.100435

[3] Fernando WD, Vincent A, Magraith K. Premature ovarian insufficiency and infertility. Aust J Gen Pract. 2023;52(1-2):32–38. DOI: 10.31128/AJGP-08-22-6531

[4] Fernando W.D, Vincent A., Magraith K. Premature ovarian insufficiency and infertility // Aust. J. Gen. Pract. 2023. Vol. 52. No. 1–2. P. 32–38. DOI: 10.31128/AJGP-08-22-6531

[5] Wesevich V, Kellen AN, Pal L. Recent advances in understanding primary ovarian insufficiency. F1000Res. 2020;9. DOI: 10.12688/F1000RESEARCH.26423.1

[6] Wesevich V., Kellen A.N., Pal L. Recent advances in understanding primary ovarian insufficiency // F1000Res. 2020. Vol. 9. DOI: 10.12688/F1000RESEARCH.26423.1

[7] Chen M, Jiang H, Zhang C. Selected genetic factors associated with primary ovarian insufficiency. Int J Mol Sci. 2023;24(5):4423. DOI: 10.3390/IJMS24054423

[8] Chen M., Jiang H., Zhang C. Selected genetic factors associated with primary ovarian insufficiency // Int. J. Mol. Sci. 2023. Vol. 24. No. 5. P. 4423. DOI: 10.3390/IJMS24054423

[9] Coulam CB, Adamson SC, Annegers JF. Incidence of premature ovarian failure. Obstetrics and Gynecology. 1986;67(4):604–606. DOI: 10.1097/00006254-198742030-00020

[10] Coulam C.B., Adamson S.C., Annegers J.F. Incidence of premature ovarian failure // Obstet. Gynecol. 1986. Vol. 67. No. 4. P. 604–606. DOI: 10.1097/00006254-198742030-00020

[11] Luborsky JL, Meyer P, Sowers MF, et al. Premature menopause in a multi-ethnic population study of the menopause transition. Hum Reprod. 2003;18(1):199–206. DOI: 10.1093/HUMREP/DEG005

[12] Luborsky J.L., Meyer P., Sowers M.F., et al. Premature menopause in a multi-ethnic population study of the menopause transition // Hum. Reprod. 2003. Vol. 18. No. 1. P. 199–206. DOI: 10.1093/HUMREP/DEG005

[13] Lagergren K, Hammar M, Nedstrand E, et al. The prevalence of primary ovarian insufficiency in Sweden; a national register study. BMC Womens Health. 2018;18(1):175. DOI: 10.1186/s12905-018-0665-2

[14] Lagergren K., Hammar M., Nedstrand E., et al. The prevalence of primary ovarian insufficiency in Sweden; a national register study // BMC Womens Health. 2018. Vol. 18. No. 1. P. 175. DOI: 10.1186/s12905-018-0665-2

[15] Golezar S, Ramezani Tehrani F, Khazaei S, et al. The global prevalence of primary ovarian insufficiency and early menopause: a meta-analysis. Climacteric. 2019;22(4):403–411. DOI: 10.1080/13697137.2019.1574738

[16] Golezar S., Ramezani Tehrani F., Khazaei S., et al. The global prevalence of primary ovarian insufficiency and early menopause: a meta-analysis // Climacteric. 2019. Vol. 22. No. 4. P. 403–411. DOI: 10.1080/13697137.2019.1574738

[17] Li K, Chen G, Hou H, et al. Analysis of sex hormones and menstruation in COVID-19 women of child-bearing age. Reprod Biomed Online. 2021;42(1):260–267. DOI: 10.1016/J.RBMO.2020.09.020

[18] Li K., Chen G., Hou H., et al. Analysis of sex hormones and menstruation in COVID-19 women of child-bearing age // Reprod. Biomed. Online. 2021. Vol. 42. No. 1. P. 260–267. DOI: 10.1016/J.RBMO.2020.09.020

[19] Ding T, Wang T, Zhang J, et al. Analysis of ovarian injury associated with COVID-19 disease in reproductive-aged women in Wuhan, China: an observational study. Front Med. 2021;8. DOI: 10.3389/FMED.2021.635255

[20] Ding T., Wang T., Zhang J., et al. Analysis of ovarian injury associated with COVID-19 disease in reproductive-aged women in Wuhan, China: an observational study // Front. Med. 2021. Vol. 8. DOI: 10.3389/FMED.2021.635255

[21] Henarejos-Castillo I, Sebastian-Leon P, Devesa-Peiro A, et al. SARS-CoV-2 infection risk assessment in the endometrium: viral infection-related gene expression across the menstrual cycle. Fertil Steril. 2020;114(2):223–232. DOI: 10.1016/j.fertnstert.2020.06.026

[22] Henarejos-Castillo I., Sebastian-Leon P., Devesa-Peiro A., et al. SARS-CoV-2 infection risk assessment in the endometrium: viral infection-related gene expression across the menstrual cycle // Fertil. Steril. 2020;. Vol. 114. No. 2. P. 223–232. DOI: 10.1016/j.fertnstert.2020.06.026

[23] Herr D, Bekes I, Wulff C. Local renin-angiotensin system in the reproductive system. Front Endocrinol. 2013;4:150. DOI: 10.3389/fendo.2013.00150

[24] Herr D., Bekes I., Wulff C. Local renin-angiotensin system in the reproductive system // Front. Endocrinol. 2013. Vol. 4. P. 150. DOI: 10.3389/fendo.2013.00150

[25] Webber L, Davies M, Anderson R, et al. ESHRE Guideline: management of women with premature ovarian insufficiency. Hum Reprod. 2016;31(5):926–937. DOI: 10.1093/HUMREP/DEW027

[26] Webber L., Davies M., Anderson R., et al. ESHRE Guideline: management of women with premature ovarian insufficiency // Hum. Reprod. 2016. Vol. 31. No. 5. P. 926–937. DOI: 10.1093/HUMREP/DEW027

[27] Tugrul Ersak D, Yilmaz N, Cavkaytar S, et al. Investigation of the role of serum telomerase levels in patients with occult primary ovarian insufficiency: a prospective cross-sectional study. J Obstet Gynaecol. 2022;42(3):485–489. DOI: 10.1080/01443615.2021.1916807

[28] Tugrul Ersak D., Yilmaz N., Cavkaytar S., et al. Investigation of the role of serum telomerase levels in patients with occult primary ovarian insufficiency: a prospective cross-sectional study // J. Obstet. Gynaecol. 2022. Vol. 42. No. 3. P. 485–489. DOI: 10.1080/01443615.2021.1916807

[29] Mohamed SA, Shalaby S, Brakta S, et al. Umbilical cord blood mesenchymal stem cells as an infertility treatment for chemotherapy induced premature ovarian insufficiency. Biomedicines. 2019;7(1):7. DOI: 10.3390/biomedicines7010007

[30] Mohamed S.A., Shalaby S., Brakta S., et al. Umbilical cord blood mesenchymal stem cells as an infertility treatment for chemotherapy induced premature ovarian insufficiency // Biomedicines. 2019. Vol. 7. No. 1. P. 7. DOI: 10.3390/biomedicines7010007

[31] Kalich-Philosoph L, Roness H, Carmely A, et al. Cyclophosphamide triggers follicle activation and “burnout”; AS101 prevents follicle loss and preserves fertility. Sci Transl Med. 2013;5(185). DOI: 10.1126/scitranslmed.3005402

[32] Kalich-Philosoph L., Roness H., Carmely A., et al. Cyclophosphamide triggers follicle activation and “burnout”; AS101 prevents follicle loss and preserves fertility // Sci. Transl. Med. 2013. Vol. 5. No. 185. DOI: 10.1126/scitranslmed.3005402

[33] Li H, Song D, Zhong Y, et al. Human umbilical cord mesenchymal stem cells therapy in cyclophosphamide-induced premature ovarian failure rat model. Biomed Res Int. 2016;2016. DOI: 10.1155/2016/2517514

[34] Li H., Song D., Zhong Y., et al. Human umbilical cord mesenchymal stem cells therapy in cyclophosphamide-induced premature ovarian failure rat model // Biomed. Res. Int. 2016. Vol. 2016. DOI: 10.1155/2016/2517514

[35] Manshadi MD, Navid S, Hoshino Y, et al. The effects of human menstrual blood stem cells-derived granulosa cells on ovarian follicle formation in a rat model of premature ovarian failure. Microsc Res Tech. 2019;82(6):635–642. DOI: 10.1002/JEMT.23120

[36] Manshadi M.D., Navid S., Hoshino Y., et al. The effects of human menstrual blood stem cells-derived granulosa cells on ovarian follicle formation in a rat model of premature ovarian failure // Microsc. Res. Tech. 2019. Vol. 82. No. 6. P. 635–642. DOI: 10.1002/JEMT.23120

[37] Liu T, Li Q, Wang S, et al. Transplantation of ovarian granulosa-like cells derived from human induced pluripotent stem cells for the treatment of murine premature ovarian failure. Mol Med Rep. 2016;13(6):5053–5058. DOI: 10.3892/MMR.2016.5191

[38] Liu T., Li Q., Wang S., et.al. Transplantation of ovarian granulosa-like cells derived from human induced pluripotent stem cells for the treatment of murine premature ovarian failure // Mol. Med. Rep. 2016. Vol. 13. No. 6. P. 5053–5058. DOI: 10.3892/MMR.2016.5191

[39] Tan R, He Y, Zhang S, et al. Effect of transcutaneous electrical acupoint stimulation on protecting against radiotherapy-induced ovarian damage in mice. J Ovarian Res. 2019;12(1):65. DOI: 10.1186/S13048-019-0541-1

[40] Tan R., He Y., Zhang S., et al. Effect of transcutaneous electrical acupoint stimulation on protecting against radiotherapy-induced ovarian damage in mice // J. Ovarian Res. 2019. Vol. 12. No. 1. P. 65. DOI: 10.1186/S13048-019-0541-1

[41] Rajkovic A, Pangas SA, Ballow D, et al. NOBOX deficiency disrupts early folliculogenesis and oocyte-specific gene expression. Science. 2004;305(5687):1157–1159. DOI: 10.1126/SCIENCE.1099755

[42] Rajkovic A., Pangas S.A., Ballow D., et al. NOBOX deficiency disrupts early folliculogenesis and oocyte-specific gene expression // Science. 2004. Vol. 305. No. 5687. P. 1157–1159. DOI: 10.1126/SCIENCE.1099755

[43] Zhou Y, Qin Y, Qin Y, et al. Wdr62 is involved in female meiotic initiation via activating JNK signaling and associated with POI in humans. PLoS Genet. 2018;14(8). DOI: 10.1371/JOURNAL.PGEN.1007463

[44] Zhou Y., Qin Y., Qin Y., et al. Wdr62 is involved in female meiotic initiation via activating JNK signaling and associated with POI in humans // PLoS Genet. 2018. Vol. 14. No. 8. DOI: 10.1371/JOURNAL.PGEN.1007463

[45] Li N, Liu L. Mechanism of resveratrol in improving ovarian function in a rat model of premature ovarian insufficiency. J Obstet Gynaecol Res. 2018;44(8):1431–1438. DOI: 10.1111/JOG.13680

[46] Li N., Liu L. Mechanism of resveratrol in improving ovarian function in a rat model of premature ovarian insufficiency // J. Obstet. Gynaecol. Res. 2018. Vol. 44. No. 8. P. 1431–1438. DOI: 10.1111/JOG.13680

RIGHTS & PERMISSIONS

Eсо-Vector